CTOs on the Move

Genvion Corporation

www.genvion.ca

 
Genvion Corporation is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.genvion.ca
  • 500 Camiel Sys St
    Winnipeg, MB CAN R2J 4K2
  • Phone: 204.663.2866

Executives

Name Title Contact Details

Similar Companies

Ostomy

RPS Pharmacy is an affiliate of Millenium Pharmaceuticals and as such, we are committed to quality healthcare with an honest approach that values patient privacy and security. All information provided to us is legally protected under the doctor-patient

Clinuvel

Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proneuron Biotechnologies

Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rondo-Pak

Rondo-Pak is a global print and packaging specialist providing effective solutions and comprehensive services to the pharmaceutical and life sciences industries. The company`s portfolio of sophisticated packaging solutions addresses precise requirements for compliance, child resistance, anti-counterfeiting e-pedigree and more. Rondo-Pak has been a recognized leader in pharmaceutical folding cartons for over 70 years, and is a proud part of the Körber Medipak network of companies.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.